Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Unicef

- PMLiVE

GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal

GSK will evaluate the therapy in combination with its own hepatitis B treatment

- PMLiVE

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

WHO publishes new infodemic management tools for pandemic preparedness

The taxonomy will support pandemic planning for respiratory pathogen disease events

- PMLiVE

GSK’s RSV vaccine Arexvy shows promise in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

- PMLiVE

WHO releases 13 interventions to help address antimicrobial resistance

The organisation has declared AMR as one of the top ten threats to global public health

- PMLiVE

GSK survey results highlight meningitis knowledge gaps among parents

More than 90% of parents did not know all three common symptoms of the infection

- PMLiVE

WHO recommends second malaria vaccine for children

The addition of R21/Matrix-M to the organisation’s list is expected to result in sufficient malaria vaccine supply

- PMLiVE

GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia

Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

World Health Organization classifies EG.5 as a COVID-19 ‘variant of interest’

The strain accounted for over 17% of COVID-19 cases between 17 and 23 July

- PMLiVE

GSK discovers strain of bacterium that stops malaria transmission

It is hoped that the discovery could contribute to the eradication of the disease

- PMLiVE

GSK files lawsuit against Pfizer over RSV vaccine patent infringement

The RSV vaccine market is estimated to exceed $5bn and could surpass $10bn by 2030

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links